Suppr超能文献

胃癌中组织蛋白酶D的免疫组化评估:其对临床预后的影响

An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.

作者信息

Allgayer H, Babic R, Grützner K U, Beyer B C, Tarabichi A, Wilhelm Schildberg F, Heiss M M

机构信息

Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany.

出版信息

Cancer. 1997 Jul 15;80(2):179-87. doi: 10.1002/(sici)1097-0142(19970715)80:2<179::aid-cncr2>3.0.co;2-p.

Abstract

BACKGROUND

In the context of tumor-associated proteolysis, the prognostic value of cathepsin D in breast carcinoma has been studied but its role is controversial in relation to gastrointestinal carcinoma. The aim of the current study was to determine whether cathepsin D is a prognostic parameter for gastric carcinoma, and also to consider interaction with the urokinase-plasminogen activator (uPA) system as an established risk factor for tumor-associated proteolysis.

METHODS

In a consecutive prospective series of 203 gastric carcinoma patients, expression of cathepsin D in tumor cells was semiquantitatively analyzed with immunohistochemistry (scored 0-3). Median follow-up time was 31 months (range, 9-56 months). Kaplan-Meier (log rank) and multivariate Cox analyses were used to analyze survival.

RESULTS

Kaplan-Meier analysis (log rank statistics) revealed significant association of increasing cathepsin D detection with poorer disease free survival (P = 0.0042) and poorer overall survival (P = 0.0018) of curatively resected patients. Overall survival of all patients was not significantly correlated. Multivariate analysis of established risk factors for gastric carcinoma, including the uPA system, identified cathepsin D as a new and independent prognostic parameter for disease free survival (P = 0.020; relative risk, 2.98; 95% confidence interval, 1.28-6.91). Plasminogen activator inhibitor type-1 as a representative of the uPA system was confirmed as a strong independent factor for disease free and overall survival. Chi-square analysis showed significant correlation of higher cathepsin D levels with Laurén's diffuse-type carcinomas and strong evidence of uPA receptor in tumor cells. However, a subgroup analysis performed according to Laurén's classification revealed a univariate prognostic impact of cathepsin D on both diffuse and intestinal types without independent value. For patients with high levels of uPA receptor (scores of 2 and 3, n = 132), a highly significant association of increasing evidence of cathepsin D with disease free survival (P < 0.0001) and overall survival (P < 0.0001) was observed for curatively resected patients. Significant association with survival was also observed for all patients (P = 0.0407).

CONCLUSIONS

Cathepsin D is a new functional prognostic parameter for gastric carcinoma patients with independent value for disease free survival. Moreover, this study indicates that consideration of more than one tumor-associated protease could lead to a more individualized estimation of risk for carcinoma patients.

摘要

背景

在肿瘤相关蛋白水解的背景下,组织蛋白酶D在乳腺癌中的预后价值已得到研究,但在胃肠道癌方面其作用仍存在争议。本研究的目的是确定组织蛋白酶D是否为胃癌的预后参数,并探讨其与尿激酶型纤溶酶原激活剂(uPA)系统(作为肿瘤相关蛋白水解的既定危险因素)之间的相互作用。

方法

在连续纳入的203例胃癌患者前瞻性系列研究中,采用免疫组织化学方法对肿瘤细胞中组织蛋白酶D的表达进行半定量分析(评分0 - 3分)。中位随访时间为31个月(范围9 - 56个月)。采用Kaplan - Meier(对数秩)和多因素Cox分析来分析生存情况。

结果

Kaplan - Meier分析(对数秩统计)显示,组织蛋白酶D检测水平升高与根治性切除患者较差的无病生存率(P = 0.0042)和较差的总生存率(P = 0.0018)显著相关。所有患者的总生存率无显著相关性。对包括uPA系统在内的胃癌既定危险因素进行多因素分析,确定组织蛋白酶D为无病生存的新的独立预后参数(P = 0.020;相对风险,2.98;95%置信区间,1.28 - 6.91)。作为uPA系统代表的纤溶酶原激活剂抑制剂-1被确认为无病生存和总生存的强独立因素。卡方分析显示,较高的组织蛋白酶D水平与Laurén弥漫型癌显著相关,且肿瘤细胞中uPA受体有充分证据。然而,根据Laurén分类进行的亚组分析显示,组织蛋白酶D对弥漫型和肠型均有单因素预后影响,但无独立价值。对于uPA受体水平高(评分2和3,n = 132)的患者,根治性切除患者中,组织蛋白酶D证据增加与无病生存率(P < 0.0001)和总生存率(P < 0.0001)高度显著相关。所有患者中也观察到与生存的显著相关性(P = 0.0407)。

结论

组织蛋白酶D是胃癌患者无病生存具有独立价值的新的功能性预后参数。此外,本研究表明,考虑多种肿瘤相关蛋白酶可能会对癌症患者风险进行更个体化的评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验